Skip to main content

Definitions
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARR, absolute rate reduction; BID, twice daily; BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular filtration rate; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HR, hazard ratio; IV, intravenous; LAE, left atrial enlargement; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; MRA, mineralocorticoid receptor antagonist; NS, not significant; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; NYHA, New York Heart Association; RASi, renin-angiotensin system inhibitor; RR, rate reduction.

References
1. Vaduganathan M, Claggett BL, Greene SJ, et al. Potential implications of expanded US food and drug administration labeling for sacubitril/valsartan in the US. JAMA Cardiol. Published online September 15, 2021. doi:10.1001/jamacardio.2021.3651
2. ENTRESTO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp. 
3. US Food and Drug Administration. Novartis cardiovascular and renal drugs advisory committee briefing document, December 15, 2020. ENTRESTO® (sacubitril/valsartan) for chronic heart failure and preserved ejection fraction. Accessed May 3, 2023. https://www.fda.gov/media/144379/download
4. Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609-1620. doi:10.1056/NEJMoa1908655
5. Mentz RJ, Ward JH, Hernandez AF, et al. Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure. J Am Coll Cardiol. 2023;S0735-1097(23)05429-3. doi:10.1016/j.jacc.2023.04.019 
6. Mentz RJ, Ward JH, Hernandez AF, et al. Rationale, design and baseline characteristics of the PARAGLIDE-HF trial: sacubitril/valsartan vs valsartan in HFmrEF and HFpEF with a worsening heart failure event [published online ahead of print, February 14, 2023]. J Card Fail. 2023;S1071-9164(23)00040-4. doi:10.1016/j.cardfail.2023.02.001 
7. Data on file. Study CLCZ696DUS01. Novartis Pharmaceuticals Corp; 2023. 
8. Mentz RJ, Ward JH, Hernandez AF, et al. Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure. J Am Coll Cardiol. 2023;S0735-1097(suppl)05429-3. doi:10.1016/j.jacc.2023.04.019 
9. Bettencourt P, Azevedo A, Pimenta J, Friões F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110(15):2168-2174. doi:10.1161/01.CIR.0000144310.04433.BE 
10. Powell-Wiley TM, Ngwa J, Kebede S, et al. Impact of body mass index on heart failure by race/ethnicity from the Get With The Guidelines-Heart Failure (GWTG-HF) registry. JACC Heart Fail. 2018;6(3):233-242. doi:10.1016/j.jchf.2017.11.011 
11. Kumar V, Redfield MM, Glasgow A, et al. Incident heart failure with mildly reduced ejection fraction: frequency, characteristics, and outcomes. J Card Fail. 2023;29(2):124-134. doi:10.1016/j.cardfail.2022.10.424
12. Data on file. Study CLCZ696DUS01. Novartis Pharmaceuticals Corp; 2021.